A multicenter phase II study assessed safety and efficacy of asunaprevir and daclatasvir in patients with chronic hepatitis C virus genotype 1 infection and end-stage renal disease requiring hemodialysis
Not Applicable
- Conditions
- Chronic hepatitis C with end-stage renal disease requiring hemodialysis
- Registration Number
- JPRN-UMIN000015882
- Lead Sponsor
- Saga Study Group of Liver Diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have malignant neoplasm, including hepatocellular carcinoma. 2) Patients with decompensated cirrhosis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method